Should fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) staging exams vs. conventional staging exams be used for patients with clinical stage 3 breast cancer without symptoms suggestive of metastases?
For patients with clinical stage 3 breast cancer without symptoms suggestive of metastases, the ECIBC's Guidelines Development Group (GDG) suggests using positron emission tomography-computed tomography (PET-CT) over conventional staging exams.
Conditional recommendation for the intervention
Low certainty of the evidence
Considerations for implementation and policy making
Need to take into account the resource capacity (including human resources and financial resources and equipment) across Europe.
- Need for cost-effectiveness data.
- Need for studies evaluating follow-up of patients that would address patient important outcomes as the only data evaluated is on accuracy outcomes.